FDA says in a new guidance that limited but long-term clinical data collected outside of the U.S. (OUS) can be used to support PMAs on the condition sponsors gather postmarket data on U.S. patients to bolster their device's evidence profile.
The agency posted its final guidance "Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval" on April 8 to outline its policies on when postmarket studies can help fill in for gaps in premarket evidence. While the final guidance is almost identical to a draft guidance issued last year, it now specifically states sponsors can use data from studies conducted outside the U.S
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?